Efficacy and Safety Phase II Dose-ranging Study of SR-T100 to Treat Actinic Keratosis
by on Thursday, January 26th, 2012 | No Comments
Condition: Actinic Keratosis
Interventions: Drug: Vehicle gel; Drug: SR-T100 with 1.0% of SM; Drug: SR-T100 with 2.3% of SM
Sponsor: G&E Herbal Biotechnology Co., LTD
Not yet recruiting – verified January 2012
See original here: Efficacy and Safety Phase II Dose-ranging Study of SR-T100 to Treat Actinic Keratosis